Philips Venture Capital

Philips Venture Capital

Philips Venture Capital was established in 2000 as the corporate venture capital arm of Royal Philips, the Dutch conglomerate that pivoted from consumer electronics to health technology in the 2010s. The unit is headquartered in Eindhoven, Netherlands, and operates under the broader Philips Ventures umbrella. Its leadership team includes Margot Cooijmans as Head of Philips Ventures and Jasper Baars as Investment Manager. The firm invests across digital health, AI diagnostics, telemedicine, and medical devices, targeting companies at Series A through growth stages. It co-invests with strategic partners and VCs, providing portfolio companies access to Philips' global distribution network, regulatory expertise, and R&D capabilities. Known portfolio positions include investments in companies like Butterfly Network and Xeltis, though specific deal sizes are typically undisclosed for competitive reasons. Deployment scale is not publicly reported, and the team size is not formally disclosed, but the unit is known to operate with a lean group of investment professionals split between Eindhoven and other European hubs. The fund is structured as a strategic corporate VC, with returns measured against both financial gains and strategic value in the form of technology integration, pilot programs, or licensing deals. Recent activity includes participation in a Series B for a digital pathology startup in 2024 (per public record, 2024). Philips Venture Capital's structural differentiator is its deep integration with the parent's healthcare ecosystem. Unlike many corporate VCs, it does not require portfolio companies to use Philips products but offers access to clinical trial networks, hospital relationships, and manufacturing scale. This 'open innovation' model sets it apart from pure-financial VCs, with investments aimed at solving real clinical problems rather than just generating financial returns.